Company intelligence / Profile preview
Patronus Biotech
Guangzhou, Guangdong, Chinaluye.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Patronus Biotech has advanced multiple U-VLP-based vaccines into Phase 1 clinical trials for RSV and herpes zoster. The company’s technology is designed to overcome traditional VLP limitations by enabling broad-spectrum pathogen coverage with improved immunogenicity and manufacturing scalability. No published efficacy or safety data from completed trials as of June 2025.
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccineGenetically engineered subunit vaccineMultivalent vaccineVirus-like particle (VLP) vaccine
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Beyond the preview
Go deeper on Patronus Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Patronus Biotech.